作者: N. Wellinghausen , A.-J. Kochem , C. Disque , H. Muhl , S. Gebert
DOI: 10.1128/JCM.00567-09
关键词:
摘要: In a prospective, multicenter study of 342 blood samples from 187 patients with systemic inflammatory response syndrome, sepsis, or neutropenic fever, new commercial PCR test (SepsiTest; Molzym) was evaluated for rapid diagnosis bacteremia. The comprises universal the 16S rRNA gene, subsequent identification bacteria positive by sequence analysis amplicons. Compared to culture (BC), diagnostic sensitivity and specificity were 87.0 85.8%, respectively. Considering 34 BC-positive patients, 28 also in at least one samples, resulting patient-related 82.4%. concordance BC both negative (47 + 247)/342, i.e., 86.0%. total, 31 PCR/sequencing negative, whom result judged as possible probable true bacteremia 25. conclusion, approach facilitates detection within few hours. Despite indispensability diagnostics, SepsiTest appears be valuable tool, allowing earlier pathogen-adapted antimicrobial therapy critically ill patients.